Oxford BioMedica Announces Six-Month Efficacy Results With Low Dose of ProSavin in Phase I/II Trial in Parkinson’s Disease
OXFORD, England, Nov. 19, 2008
- Improvements in Motor Function Maintained at Six Months -
http://www.pharmalive.com/News/index...&categoryid=40